$ORMP
ORAMED PHARMACEUTICALS INC. Stock $ormp

$ormp Overview Financials Valuation SEC Filings Company Website

2012 Q1 Form 10-Q Financial Statement

#000117891312000118 Filed on January 12, 2012

Income Statement

Concept	2012 Q1	2011 Q4	2010 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$230.0K	$280.0K	$320.0K
YoY Change	-25.81%	-12.5%	10.34%
% of Gross Profit
Research & Development	$710.6K	$184.0K	$286.5K
YoY Change	108.2%	-35.77%	-13.19%
% of Gross Profit
Depreciation & Amortization	$0.00	$6.042K	$7.451K
YoY Change	-100.0%	-18.91%	-25.49%
% of Gross Profit
Operating Expenses	$710.6K	$184.0K	$286.5K
YoY Change	108.2%	-35.77%	-53.79%
Operating Profit	-$940.4K	-$465.9K	-$601.6K
YoY Change	45.29%	-22.56%
Interest Expense	$0.00	-$10.00K	$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$985.4K	-$478.5K	-$602.8K
YoY Change	53.3%	-20.62%	-1.18%
Income Tax
% Of Pretax Income
Net Earnings	-$985.4K	-$478.5K	-$602.8K
YoY Change	53.3%	-20.62%	-1.18%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$169.2K	-$82.19K	-$124.2K
COMMON SHARES
Basic Shares Outstanding	70.19M
Diluted Shares Outstanding

Balance Sheet

Concept	2012 Q1	2011 Q4	2010 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.000M	$3.680M	$1.100M
YoY Change	-19.14%	234.55%	-56.86%
Cash & Equivalents	$1.824M	$1.496M	$1.101M
Short-Term Investments	$1.180M	$2.190M	$0.00
Other Short-Term Assets	$30.00K	$40.00K	$40.00K
YoY Change	-25.0%	0.0%	0.0%
Inventory
Prepaid Expenses	$12.81K	$18.52K
Receivables	$46.67K	$86.00K	$20.00K
Other Receivables	$28.05K	$63.96K	$150.0K
Total Short-Term Assets	$3.108M	$3.865M	$1.310M
YoY Change	-19.06%	195.08%	-54.51%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.792K	$11.33K	$40.00K
YoY Change	-74.03%	-71.67%	-42.86%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$10.00K	$10.00K	$10.00K
YoY Change	-66.67%	0.0%	0.0%
Other Assets	$20.00K	$10.00K
YoY Change
Total Long-Term Assets	$34.31K	$37.09K	$50.00K
YoY Change	-31.39%	-25.81%	-37.5%
TOTAL ASSETS
Total Short-Term Assets	$3.108M	$3.865M	$1.310M
Total Long-Term Assets	$34.31K	$37.09K	$50.00K
Total Assets	$3.143M	$3.903M	$1.360M
YoY Change	-19.21%	186.95%	-54.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$530.0K	$360.0K	$340.0K
YoY Change	1.92%	5.88%	-5.56%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$582.2K	$424.4K	$380.0K
YoY Change	2.13%	11.68%	-7.32%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$160.0K	$160.0K	$160.0K
YoY Change	0.0%	0.0%	6.67%
Total Long-Term Liabilities	$162.0K	$160.8K	$160.0K
YoY Change	1.27%	0.51%	6.67%
TOTAL LIABILITIES
Total Short-Term Liabilities	$582.2K	$424.4K	$380.0K
Total Long-Term Liabilities	$162.0K	$160.8K	$160.0K
Total Liabilities	$744.1K	$585.2K	$540.0K
YoY Change	1.94%	8.37%	-3.57%
SHAREHOLDERS EQUITY
Retained Earnings	-$16.01M	-$15.03M
YoY Change
Common Stock	$18.41M	$18.35M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.398M	$3.317M	$810.0K
YoY Change
Total Liabilities & Shareholders Equity	$3.143M	$3.903M	$1.360M
YoY Change	-19.21%	186.95%	-54.05%

Cashflow Statement

Concept	2012 Q1	2011 Q4	2010 Q4
OPERATING ACTIVITIES
Net Income	-$985.4K	-$478.5K	-$602.8K
YoY Change	53.3%	-20.62%	-1.18%
Depreciation, Depletion And Amortization	$0.00	$6.042K	$7.451K
YoY Change	-100.0%	-18.91%	-25.49%
Cash From Operating Activities	-$600.0K	-$484.1K	-$498.4K
YoY Change	200.0%	-2.87%	193.15%
INVESTING ACTIVITIES
Capital Expenditures	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$960.0K	$1.061K
YoY Change	-153.93%
Cash From Investing Activities	$960.0K	$448.9K	$100.0K
YoY Change	-153.93%	348.94%	-125.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000		$300.0K
YoY Change	-100.0%
NET CHANGE
Cash From Operating Activities	-600.0K	-$484.1K	-$498.4K
Cash From Investing Activities	960.0K	$448.9K	$100.0K
Cash From Financing Activities	0.000		$300.0K
Net Change In Cash	360.0K	-$35.13K	-$98.36K
YoY Change	-56.63%	-64.28%	-82.74%
FREE CASH FLOW
Cash From Operating Activities	-$600.0K	-$484.1K	-$498.4K
Capital Expenditures	$0.00
Free Cash Flow	-$600.0K	-$484.1K	-$498.4K
YoY Change	200.0%	-2.87%	193.15%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2011Q4	dei	Amendment Flag AmendmentFlag	false
CY2011Q4	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--08-31
CY2011Q4	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2011Q4	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2012
CY2011Q4	dei	Document Period End Date DocumentPeriodEndDate	2011-11-30
CY2011Q4	dei	Document Type DocumentType	10-Q
CY2011Q4	dei	Entity Central Index Key EntityCentralIndexKey	0001176309
CY2012Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	70187583
CY2011Q4	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2011Q4	dei	Entity Registrant Name EntityRegistrantName	ORAMED PHARMACEUTICALS INC.
CY2011Q4	ormp	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants	6502	USD
CY2011	ormp	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants	26733	USD
	ormp	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Consultants AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionConsultants	615882	USD
CY2011	ormp	Adjustment To Additional Paid In Capital Imputed Interest AdjustmentToAdditionalPaidInCapitalImputedInterest	3782	USD
	ormp	Adjustment To Additional Paid In Capital Imputed Interest AdjustmentToAdditionalPaidInCapitalImputedInterest	19777	USD
CY2011Q4	ormp	Discount On Convertible Note Related To Beneficial Conversion Feature DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature		USD
CY2010Q4	ormp	Discount On Convertible Note Related To Beneficial Conversion Feature DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature		USD
	ormp	Discount On Convertible Note Related To Beneficial Conversion Feature DiscountOnConvertibleNoteRelatedToBeneficialConversionFeature	108000	USD
CY2011Q4	ormp	Imputed Interest Expense ImputedInterestExpense		USD
CY2010Q4	ormp	Imputed Interest Expense ImputedInterestExpense	947	USD
	ormp	Imputed Interest Expense ImputedInterestExpense	23559	USD
CY2011Q4	ormp	Issuance Of Stock And Warrants To Be Issued For Services Or Claims IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims	24900	USD
CY2010Q4	ormp	Issuance Of Stock And Warrants To Be Issued For Services Or Claims IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims		USD
CY2011Q4	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		USD
	ormp	Issuance Of Stock And Warrants To Be Issued For Services Or Claims IssuanceOfStockAndWarrantsToBeIssuedForServicesOrClaims	24900	USD
CY2011Q4	ormp	Proceeds From Receipts On Account Of Shares Issuances ProceedsFromReceiptsOnAccountOfSharesIssuances		USD
CY2010Q4	ormp	Proceeds From Receipts On Account Of Shares Issuances ProceedsFromReceiptsOnAccountOfSharesIssuances		USD
	ormp	Proceeds From Receipts On Account Of Shares Issuances ProceedsFromReceiptsOnAccountOfSharesIssuances	6061	USD
	ormp	Receipts On Account Of Shares And Warrants ReceiptsOnAccountOfSharesAndWarrants	6061	USD
CY2011	ormp	Stock Issued During Period Value Services StockIssuedDuringPeriodValueServices	227569	USD
	ormp	Stock Issued During Period Value Services StockIssuedDuringPeriodValueServices	617638	USD
CY2011Q4	ormp	Stock Issued During Period Value Services Rendered StockIssuedDuringPeriodValueServicesRendered	24900	USD
CY2011Q4	ormp	Weighted Average Number Of Basic And Diluted Shares Used In Computation Of Loss Per Share WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare	70104583
CY2010Q4	ormp	Weighted Average Number Of Basic And Diluted Shares Used In Computation Of Loss Per Share WeightedAverageNumberOfBasicAndDilutedSharesUsedInComputationOfLossPerShare	57932597
CY2011Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	357282	USD
CY2011Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	375538	USD
CY2011Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	47252	USD
CY2011Q3	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	47252	USD
CY2011Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	86000	USD
CY2011Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	542891	USD
CY2011Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4221	USD
CY2011Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax		USD
CY2011Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	18277307	USD
CY2011Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	18201111	USD
	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	108000	USD
	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	18991	USD
CY2011Q4	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	44794	USD
CY2011	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	502593	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	3554921	USD
CY2010Q4	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	108000	USD
CY2011Q4	us-gaap	Assets Assets	3902577	USD
CY2011Q3	us-gaap	Assets Assets	4325937	USD
CY2011Q4	us-gaap	Assets Current AssetsCurrent	3865484	USD
CY2011Q3	us-gaap	Assets Current AssetsCurrent	4284082	USD
CY2002Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue		USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1495615	USD
CY2011Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1513365	USD
CY2010Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1199638	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1101283	USD
CY2009Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1716866	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-17750	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-98355	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1495615	USD
CY2011Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2011Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2011Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2011Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2011Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70104583
CY2011Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	70104583
CY2011Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	70104583
CY2011Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	70104583
CY2011Q4	us-gaap	Common Stock Value CommonStockValue	70104	USD
CY2011Q3	us-gaap	Common Stock Value CommonStockValue	70104	USD
CY2011Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4205	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16	USD
CY2011Q4	us-gaap	Contribution Of Property ContributionOfProperty		USD
CY2010Q4	us-gaap	Contribution Of Property ContributionOfProperty		USD
	us-gaap	Contribution Of Property ContributionOfProperty	18991	USD
CY2011Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	1805030	USD
CY2011Q3	us-gaap	Deposits Assets Current DepositsAssetsCurrent	1801400	USD
CY2011Q4	us-gaap	Depreciation Depreciation	6042	USD
CY2010Q4	us-gaap	Depreciation Depreciation	7451	USD
	us-gaap	Depreciation Depreciation	112149	USD
CY2011Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	19838	USD
CY2011Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	18502	USD
CY2011Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.01
CY2010Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.01
CY2011Q4	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	3849	USD
CY2010Q4	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	385	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	6517	USD
CY2011Q4	us-gaap	Gain Loss On Investments Excluding Other Than Temporary Impairments GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments		USD
CY2010Q4	us-gaap	Gain Loss On Investments Excluding Other Than Temporary Impairments GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments		USD
	us-gaap	Gain Loss On Investments Excluding Other Than Temporary Impairments GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments	1033004	USD
CY2011Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	281901	USD
CY2010Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	315129	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7240284	USD
CY2011Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-478519	USD
CY2010Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-602784	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14875244	USD
CY2011Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
CY2010Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	150558	USD
CY2011Q4	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-16920	USD
CY2010Q4	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-76182	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	377120	USD
CY2011Q4	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities		USD
CY2010Q4	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities		USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	138054	USD
CY2011Q4	us-gaap	Increase Decrease In Pension And Postretirement Obligations IncreaseDecreaseInPensionAndPostretirementObligations	88	USD
CY2010Q4	us-gaap	Increase Decrease In Pension And Postretirement Obligations IncreaseDecreaseInPensionAndPostretirementObligations		USD
	us-gaap	Increase Decrease In Pension And Postretirement Obligations IncreaseDecreaseInPensionAndPostretirementObligations	22763	USD
CY2011Q4	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	49727	USD
CY2010Q4	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	111494	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	167685	USD
CY2011Q4	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash		USD
CY2010Q4	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash		USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	7509	USD
CY2011Q4	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities		USD
CY2010Q4	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	9	USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	16000	USD
CY2011Q4	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	11290	USD
CY2011Q3	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	10186	USD
CY2011Q4	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		USD
CY2010Q4	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	88800	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1048096	USD
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3902577	USD
CY2011Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4325937	USD
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	424372	USD
CY2011Q3	us-gaap	Liabilities Current LiabilitiesCurrent	441292	USD
CY2011Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	160817	USD
CY2011Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	160729	USD
CY2011Q4	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	138054	USD
CY2011Q3	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	138054	USD
CY2011Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	380359	USD
CY2011Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	384565	USD
CY2011Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		USD
CY2010Q4	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	300000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12002997	USD
CY2011Q4	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	448939	USD
CY2010Q4	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	100000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1496728	USD
CY2011Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-466689	USD
CY2010Q4	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-498355	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9010654	USD
CY2011Q4	us-gaap	Net Income Loss NetIncomeLoss	-478519	USD
CY2010Q4	us-gaap	Net Income Loss NetIncomeLoss	-602784	USD
	us-gaap	Net Income Loss NetIncomeLoss	-15025802	USD
CY2011	us-gaap	Net Income Loss NetIncomeLoss	-1561245	USD
	us-gaap	Net Income Loss NetIncomeLoss	-12986038	USD
CY2011Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-465917	USD
CY2010Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-601617	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-15711025	USD
CY2011Q4	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	19556	USD
CY2010Q4	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	3356	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	200813	USD
CY2011Q4	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	6954	USD
CY2010Q4	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	2189	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	201002	USD
CY2011Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	63961	USD
CY2011Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	24191	USD
CY2011Q4	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet		USD
CY2010Q4	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet		USD
	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet	434876	USD
CY2011Q4	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities		USD
CY2010Q4	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities		USD
	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNetAvailableforsaleSecurities	197412	USD
CY2011Q4	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	1061	USD
CY2010Q4	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities		USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	15354	USD
CY2011Q4	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		USD
CY2010Q4	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	123483	USD
CY2011Q4	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments		USD
CY2010Q4	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments		USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	5428382	USD
CY2011Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	22763	USD
CY2011Q3	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	22675	USD
CY2011Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	18519	USD
CY2011Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1670	USD
CY2011Q4	us-gaap	Prepaid Pension Costs PrepaidPensionCosts	14469	USD
CY2011Q3	us-gaap	Prepaid Pension Costs PrepaidPensionCosts	14293	USD
CY2011Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		USD
CY2010Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	275000	USD
CY2011Q4	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity		USD
CY2010Q4	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	300000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	11655693	USD
CY2011Q4	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		USD
CY2010Q4	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	120000	USD
CY2011Q4	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		USD
CY2010Q4	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	66243	USD
CY2011Q4	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments		USD
CY2010Q4	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	100000	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	3628000	USD
CY2011Q4	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	450000	USD
CY2010Q4	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments		USD
	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	450000	USD
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11334	USD
CY2011Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17376	USD
CY2011Q4	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		USD
CY2010Q4	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable		USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	120000	USD
CY2011Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	184016	USD
CY2010Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	286488	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8035865	USD
CY2011Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	16000	USD
CY2011Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	16000	USD
CY2011Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15025802	USD
CY2011Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-14547299	USD
CY2011Q4	us-gaap	Share Based Compensation ShareBasedCompensation	51296	USD
CY2010Q4	us-gaap	Share Based Compensation ShareBasedCompensation	195301	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4751425	USD
CY2002Q2	us-gaap	Stockholders Equity StockholdersEquity	53700	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	3317388	USD
CY2011Q3	us-gaap	Stockholders Equity StockholdersEquity	3723916	USD
CY2010Q3	us-gaap	Stockholders Equity StockholdersEquity	830272	USD
CY2009Q3	us-gaap	Stockholders Equity StockholdersEquity	2746192	USD
CY2011Q4	us-gaap	Stock Issued1 StockIssued1		USD
CY2010Q4	us-gaap	Stock Issued1 StockIssued1		USD
	us-gaap	Stock Issued1 StockIssued1	77779	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	275000	USD
CY2011	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3694212	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7907781	USD
	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	434876	USD

Files In Submission

Name	View Source	Status
0001178913-12-000118-index-headers.html	Edgar Link	pending
0001178913-12-000118-index.html	Edgar Link	pending
0001178913-12-000118.txt	Edgar Link	pending
0001178913-12-000118-xbrl.zip	Edgar Link	pending
exhibit_31-1.htm	Edgar Link	pending
exhibit_31-2.htm	Edgar Link	pending
exhibit_32-1.htm	Edgar Link	pending
exhibit_32-2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
ormp-20111130.xml	Edgar Link	completed
ormp-20111130.xsd	Edgar Link	pending
ormp-20111130_cal.xml	Edgar Link	unprocessable
ormp-20111130_def.xml	Edgar Link	unprocessable
ormp-20111130_lab.xml	Edgar Link	unprocessable
ormp-20111130_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
zk1210890.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ORMP
ORAMED PHARMACEUTICALS INC. Stock $ormp

2012 Q1 Form 10-Q Financial Statement

#000117891312000118 Filed on January 12, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ORMP ORAMED PHARMACEUTICALS INC. Stock $ormp

2012 Q1 Form 10-Q Financial Statement

#000117891312000118 Filed on January 12, 2012

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ORMP
ORAMED PHARMACEUTICALS INC. Stock $ormp